1 Min Read
April 7 (Reuters) - Kura Oncology Inc:
* Kura Oncology doses first patient in phase 1 trial of ERK Inhibitor KO-947 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.